Creative Biolabs Releases SARS-CoV-2 Vaccine Discovery Services in Response to COVID-19
As the data showed on April 23, 2020, there were approximately 2,638,909 global cases of COVID-19 with 722,055 recovered and 184,249 deaths. The United States, Italy, and Spain have been the three countries hardest hit by the pandemic. Developing the specific vaccine is imperative and urgent.
As a top-class institution as well as experienced supplier in biotech markets, Creative Biolabs has more than a decade of experience and expertise in vaccine discovery and development, and is committed to supporting the SARS vaccine research and development industry with its SARS-CoV-2 vaccine development services.
• In Silico Vaccine Design for SARS-CoV-2
The in silico vaccine development platform at Creative Biolabs contains epitope screening tools, which can be used to identify potential epitopes in protein vaccine targets. Driven by sequence information, structural bioinformatics, and experimental data, these tools can predict peptide/HLA binding, and HLA Class I CD8+ and CD4+T cell epitopes. To provide the optimal amounts of antigen that confers the broadest protection against SARS-CoV-2 infection, the screening tools can identify conserved regions in multiple SARS-CoV-2 strains to help design vaccines with maximum coverage.
• Live Attenuated and Killed Vaccine Development Services for SARS-CoV-2
Among the many types of vaccines, live attenuated and inactivated vaccines constitute the vast majority of vaccines currently in use. Creative Biolabs offers a variety of vaccine design services for SARS-CoV-2, including live attenuated and inactivated vaccines, which cover all the stages in the vaccine development, including isolation and identification of virus strains, virus cultivation, inactivation, etc.
• Recombinant Subunit Vaccine Development Services for SARS-CoV-2
Similar to other enveloped RNA viruses, SARS-CoV-2 has a SARS spike protein, trimeric S protein, on its viral envelope. Since this protein is responsible for binding to the host cell surface receptor ACE2 and mediating subsequent viral entry, the trimeric S protein is a very attractive candidate for developing subunit vaccines. With an innovative vaccine development platform, Creative Biolabs allows the production of novel, covalently-trimerized fusion proteins, and provides comprehensive SARS-CoV-2 S protein subunit vaccine development services, including gene synthesis, vector construction, protein expression and purification, immunoassay, etc.
Apart from the aforementioned services, mRNA vaccine development services, modified vaccinia virus vectored vaccine development services, virus-like particles based vaccine development services for SARS-CoV-2, as well as formulation optimization platform and analysis & qualification service for SARS-CoV-2 Vaccine are also available at Creative Biolabs.
Creative Biolabs has conducted extensive and in-depth research on the MERS-CoV epidemic in 2012, and thus has accumulated a lot of experience. The vaccine discovery and development related services of Creative Biolabs provide cutting-edge technical support to accelerate vaccine research from identification of potential targets to analysis of the immune response and assessment in an infectious challenge model. Further information can be found at https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs is known as a famous institute and experienced supplier in the biotech market. With abundant drug development experience over the past years, Creative Biolabs provides researchers with excellent CRO services regarding discovery services of anti-SARS-COV-2 drugs as well as vaccine development services, preclinical research services, various in vivo and in vivo research models, and in vivo diagnostic immunoassay services.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.creative-biolabs.com
